AIDS-associated mucocutaneous Kaposiʼs sarcoma treated with bleomycin

Publisher Website
Google Scholar
Abstract
To evaluate efficacy and tolerance of bleomycin in AIDS-associated mucocutaneous Kaposi's sarcoma. A previous study showed that bleomycin was effective and well tolerated in this setting. A non-comparative, open, prospective study. Seventy patients were treated with 5 mg per day intramuscular bleomycin on 3 consecutive days every 2 weeks. Two patients achieved a complete response and 50 a partial response (overall response rate, 74%). Median time to treatment response was 4 weeks (range, 2–12 weeks) and median time to relapse 10 weeks (range, 2–36 weeks). Dose-limiting toxicity consisted of cutaneous adverse reactions. Bleomycin is active against AIDS-associated mucocutaneous Kaposi's sarcoma; relapse occurs after discontinuation of therapy.

This publication has 0 references indexed in Scilit: